As our VP of Biology with three decades of experiences, Wen-Chen is excited to propel our drug programs through IND-enabling studies across multiple therapeutic areas. Before joining Octant, Wen-Chen held the position of Chief Scientific Officer at Surrozen, a trailblazing company in regenerative medicine. There, he played a pivotal role in developing innovative platforms that utilized targeted antibodies to selectively activate the Wnt pathway. His previous role was as a Scientific Executive Director at Amgen, where he led research teams in the creation of novel therapies for heart disease, diabetes, dyslipidemia, and inflammation. He also contributed to advancing several drug programs to clinical trials.
Prior to his tenure at Amgen, Dr. Yeh led a highly productive research lab at the University of Toronto, focusing on immunology and inflammatory signaling mechanisms. His medical background includes a residency in internal medicine at Mackay Memorial Hospital in Taipei and a medical internship at the National Taiwan University Hospital.